Modality
Peptide
MOA
GLP-1/GIP
Target
ALK
Pathway
Incretin
Schizophrenia
Development Pipeline
Preclinical
~Nov 2022
→ ~Feb 2024
Phase 1
May 2024
→ Feb 2031
Phase 1Current
NCT08821363
813 pts·Schizophrenia
2024-05→2031-02·Active
813 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-064.9y awayPh2 Data· Schizophrenia
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P1/2
Active
Catalysts
Ph2 Data
2031-02-06 · 4.9y away
Schizophrenia
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08821363 | Phase 1/2 | Schizophrenia | Active | 813 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Niralucimab | Ionis | Phase 1 | ALK |